Work

Abstract 1677: Navitoclax, a Bcl-2/xL inhibitor, and YM155, a survivin inhibitor, in combination with carboplatin effectively inhibit ovarian cancer tumor growth

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-1677

Authors: Tejas Samantaray, Hilary Kenny, Lucy Kelliher, Ernst R. Lengyel, Carman K.M. Ip, Kasjusz Kordylewicz, Rachael Hoffmann, Sarah Rauch, Beatrice Malacrida, Sophie Skingsley, Frances R. Balkwill, Chiara Battistini, Ugo Cavallaro, Wolf R. Wiedemeyer

Institutions: University of Chicago, Queen Mary University of London, European Institute of Oncology, AbbVie (United States)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409630529

Cites:

Cited by: 1

Related to: 10